Banqilinghua Powder Veterinary Grade API is released as a light yellow to tan, micronized, multi-constituent powder intended for further manufacture into tablets, injections, capsules, powders, granules, premixes, and solutions. The product is not assigned a separate numerical model code; it is identified by the monograph name Banqilinghua Powder and the grade suffix Veterinary Grade API. Import and formulation records generally use the manufacturer’s registered trade name, batch number, and the applicable dosage-form compatibility code. The material is supplied in sealed polyethylene-aluminium composite bags or fibre drums with an inner food-contact liner. Standard package sizes are 1 kg, 5 kg, and 25 kg net, although intermediate bulk containers are available for large-volume granulation suites.

The bulk powder is controlled for particle size distribution by laser diffraction using ISO 13320-1. The fine grade is specified with a D90 of ≤ 75 µm, and the standard grade with a D90 of ≤ 150 µm. The particle size target is set to maintain blend uniformity in low-dose dry blends and to minimise segregation when the API is mixed with coarse carriers in premixes. Bulk density is typically between 0.35 g/mL and 0.65 g/mL, with tapped density reported according to USP <616> Method I. Hausner ratios between 1.20 and 1.45 indicate fair to passable flow; formulations requiring direct compression may need flow aids such as colloidal silicon dioxide at 0.5% to 1.5% w/w. These values are release specifications, not universal formulation guarantees, and each dosage form must be validated on the actual production equipment. The product is not sterile and is not intended for direct administration without pharmaceutical processing.

Why Does the Veterinary Grade Designation Change Batch Release Conditions?

The veterinary grade designation requires release against pharmaceutical controls that are not consistently applied to feed-grade or crude botanical powders. The primary difference is the application of pharmacopoeial limits for microbial enumeration, heavy metals, ash, and moisture. For this product, batch release should be aligned with the general framework of USP <61>, USP <62>, USP <561>, USP <731>, and ICH Q3D. Residual solvent limits follow VICH GL18 where extraction solvents are used in manufacture. The certificate of analysis reports identity by high-performance liquid chromatography or thin-layer chromatography against a designated reference substance. Marker assay content is expressed on a dry basis, so moisture correction is mandatory when calculating the charge weight for a batch.

The release criteria below represent the veterinary API specification profile. If a finished dosage form is intended for parenteral use, the manufacturer must introduce additional testing at the finished product stage because the bulk API is supplied non-sterile.

These acceptance criteria are appropriate for solid and oral liquid dosage forms. For injectable preparations, the finished product must additionally comply with USP <71> for sterility, USP <85> for bacterial endotoxins, and USP <788> for particulate matter. The API powder itself does not carry a sterility claim. If aseptic processing is planned, the powder should be dissolved or suspended and then sterile-filtered or terminally sterilised according to the stability of the active constituents.

Micronized Powder Behaviour in Tablet, Capsule, and Granule Operations

Solid dosage manufacturing with Banqilinghua Powder Veterinary Grade API requires attention to moisture uptake, blend segregation, and compression behaviour. The powder is hygroscopic enough that pre-conditioning at 40 °C to 45 °C for 2 h to 4 h may be required when ambient relative humidity exceeds 60%. Wet granulation using aqueous binder systems can be performed, but exposure time and drying temperature should be limited because the multi-constituent botanical powder may contain heat-sensitive fractions. Fluidised bed drying at inlet temperatures above 60 °C is generally avoided unless forced degradation studies support higher exposure.

For tablet formulations, the API is typically blended with microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate. Magnesium stearate levels should remain below 0.5% w/w and blend time should be controlled to avoid overlubrication, which can reduce tablet hardness and prolong disintegration. Disintegration testing follows USP <701>. Immediate-release tablets formulated with this API should be evaluated for disintegration at 37 °C ± 2 °C; prolonged disintegration beyond 15 min may require increasing the disintegrant concentration or reducing granule density. Tablet hardness is measured by USP <1217> or a calibrated hardness tester.

Capsule filling is more sensitive to flow variation than tablet compression. The powder may be filled directly if the Hausner ratio remains below 1.25, but higher ratios often necessitate dry granulation or addition of 0.5% to 1.0% colloidal silicon dioxide. Granules for sachets and oral powders are usually prepared by wet granulation followed by extrusion-spheronisation or fluidised bed drying. Granule friability is assessed using a friability tester with a drum rotation at 25 rpm for 10 min; acceptable loss is generally ≤ 1.0% for sachet filling to avoid excessive dust generation and weight variation.

Premix manufacture introduces a different problem. The API is dispersed into a carrier such as lactose, dextrose, or corn grits. Because the API density differs from carrier density, segregation may occur during transfer or sacking. Ribbon blenders or double-cone blenders are used, with mixing time determined by blend uniformity studies. Samples are taken from 10 sampling points by USP <905> guidelines, and active marker content is measured by HPLC. The coefficient of variation should be ≤ 5.0% for a validated premix. If the coefficient exceeds 5.0%, pre-blending with a portion of carrier at a ratio of 1:3 or 1:5 is applied before final dilution.

When Aqueous Solutions or Parenteral Dosage Forms Are Required

Solution and injection manufacture requires a different processing route. Banqilinghua Powder Veterinary Grade API is only partially soluble in water, and the soluble fraction depends on pH and temperature. For oral solutions, the powder is dispersed in purified water at 40 °C to 50 °C, stirred for 30 min to 60 min, and then filtered through a 10 µm or finer clarifier. If the product requires a clear solution rather than a suspension, pH adjustment with citrate or phosphate buffer is often necessary. The target pH is typically between 5.0 and 6.5 to protect labile constituents, but the exact range must be based on forced degradation data.

For injections, the bulk powder is not directly injectable. It must be reconstituted into a sterile vehicle and filtered through a 0.22 µm sterilising membrane. The resulting solution or suspension must pass USP <71> sterility testing, USP <85> endotoxin testing, and USP <788> particulate matter testing. The pH of the injectable solution should be maintained within the range established by the stability protocol, commonly between 5.5 and 7.0, and the osmolality adjusted to 290 mOsm/kg to 310 mOsm/kg using sodium chloride or glucose. Terminal sterilisation by autoclaving at 121 °C for 15 min may not be acceptable if the active markers degrade; in that case aseptic filtration is required and the manufacturer must validate filter compatibility and extractables.

Because the API is a multi-constituent botanical powder, solution stability should be evaluated by monitoring marker content, colour change, pH drift, and precipitation over the intended shelf life. Accelerated testing at 40 °C ± 2 °C and 75% ± 5% relative humidity for 6 months provides initial degradation trends. If marker content drops by more than 5.0% from initial at the accelerated condition, reformulation or protective packaging may be required.

Granules and powders for oral administration are the least complex dosage forms but still require dissolution or dispersion testing. In veterinary practice, powders are often administered in feed or drinking water. For drinking water formulations, the API-containing powder should disperse within 5 min at 20 °C to 25 °C without foaming or clumping. Hard water can reduce dispersibility, so the formulation may require a wetting agent. Polysorbate 80 at 0.1% to 0.5% v/v is commonly used, but compatibility with the active constituents must be confirmed.

Elemental Impurity and Endotoxin Boundaries for Multi-Species Administration

The veterinary grade API differs from feed-grade powder in the control of elemental impurities and microbial load. Feed-grade botanical powders can carry lead, arsenic, cadmium, and mercury at concentrations that exceed pharmaceutical limits, particularly when the plant material is sourced from uncontrolled mineral soils. For the API, lead is controlled at ≤ 10 mg/kg, arsenic at ≤ 2 mg/kg, cadmium at ≤ 1 mg/kg, and mercury at ≤ 0.1 mg/kg unless the specific monograph imposes lower limits. These acceptance criteria are assessed by USP <233> or a validated ICP-MS method.

Endotoxin control is introduced at the finished parenteral or oral liquid stage, not at the bulk powder stage for all markets. However, if the API is labelled for injection-grade use, the manufacturer should confirm the endotoxin limit for the finished product, typically ≤ 5 EU/kg for large animals and lower for small species according to the route and dose. The API is non-sterile and cannot be assumed pyrogen-free. Processes that reduce endotoxin include depyrogenation of equipment, water-for-injection rinsing, and filtration through charged membranes. Dry heat depyrogenation of the powder itself is generally unsuitable because botanical constituents degrade at high temperature.

The comparative profile below separates the veterinary API from feed-grade botanical powder and synthetic small-molecule API. These differences are structural, not promotional.

Formulation sites should not treat Banqilinghua Powder Veterinary Grade API as a single-marker synthetic compound. The active fraction is not a purified molecule, so dissolution, assay, and impurity testing must be designed for a multi-constituent mixture. Published data for this specific configuration is limited, and formulators should rely on site-specific stability and compatibility studies. Avoid contact with strong oxidising agents and avoid prolonged exposure to alkaline conditions above pH 9, which may degrade the marker constituents. Storage should be in tightly closed containers below 25 °C and below 60% relative humidity. Re-test intervals should be assigned from long-term stability data under 25 °C ± 2 °C and 60% ± 5% relative humidity.

Process transfers across equipment scales require revalidation of blend uniformity, granule density, and compression profile. Twin-screw granulators with L/D ratios between 20:1 and 40:1 have been used for continuous wet granulation of botanical APIs, but this product requires cautious screw configuration because high mechanical energy may raise local temperature and affect marker content. Injection moulding is not applicable to this powder; the term “injections” refers to liquid parenteral dosage forms, not polymer moulding. The API is intended for veterinary use only and must be handled in accordance with current good manufacturing practice for veterinary active pharmaceutical ingredients.